A multicenter, prospective study exploring the management model of ZERO-HD in 14 hemodialysis centers in Sichuan Province

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400090386

Enrollment

Unknown

Registered

2024-09-29

Start date

2024-10-01

Completion date

Unknown

Last updated

2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis C

Interventions

DAAs treatment group:Sofobuvir/Vipataivir (SOF/VEL) 400mg/100mg once daily for 12 weeks (plus ribavirin for 12 weeks in patients with compensated hepatitis C virus genotype 3 cirrhosis

Patients with decompensated cirrhosis may be given ribavirin for 12 weeks or extended to 24 weeks)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Patients aged =18 years and undergoing maintenance hemodialysis in 14 hemodialysis centers in Sichuan Province; (2) Newly treated patients who are anti-HCV and HCV RNA positive and not anti-HCV; (3) Patients who agree to join and sign informed consent; (4) Clinical data, medical history, examination records and other data can be fully traceable; (5) Obtain approval from the Ethics Committee.

Exclusion criteria

Exclusion criteria: (1) Age <18 years old; (2) Pregnant or lactating women; (3) has any serious or active physical or mental illness (such as depression) that, in the investigator's opinion, interferes with the subject's treatment, evaluation, or protocol compliance; (4) Combined with HAV, HDV, HEV, HIV and other infected persons; (5) Patients with alcoholic liver disease, drug-induced liver injury, autoimmune liver disease, genetic metabolic liver disease, etc.; (6) suffering from malignant tumors, including hepatocellular carcinoma; (7) Incomplete clinical data, including baseline data, follow-up data or outcome data, could not meet the data analysis of this study. (8) Patients who explicitly refused to participate in this study.

Design outcomes

Primary

Measure	Time frame
HCV RNA;AFP;eGFR;Scr;	—

Secondary

Measure	Time frame
PLT;HGB;ALT;AST;ALB;TBIL;End-of -treatment virological response,ETVR);Sustained virological response,SVR);	—

Countries

China

Contacts

Public ContactXiaoxia Geng

Sichuan Academy of Medical Sciences • Sichuan Provincial People's Hospital

gengxiaoxia@126.com+86 189 8183 8225

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026